Fig 1: IL-35-STAT3 axis deregulates naive B cells in pancreatic cancer(A) Representative flow cytometry histogram plot of intracellular IL10, p35, EBi3, and surface CD1d in naive B cells isolated from oKPC mice and treated as indicated.(B) Quantification of IL10, p35, EBi3, and CD1d in naive B cells treated as in (A), with STAT1 inhibitor (left) and STAT3 inhibitor (right).(C) Quantification of Pax5 in naive B cells treated as in (A).(D) Quantification of Bcl6 in naive B cells treated as in (A).(E) ChIP analysis for enrichment of Pax5 at p35, EBi3, and Cd1d gene promoters. Naive B cells isolated from oKPC mice were treated with aCD40/LPS and ± STAT3 inhibitor for 72 h followed by ChIP analysis.(F) ChIP analysis for enrichment of H3K27ac at p35, EBi3, and Cd1d gene promoters. Naive B cells were isolated and treated as in (E).(G) Experimental schematic used to investigate in vivo effect of STAT1 (STAT1i) and STAT3 (STAT3i) inhibition in B cells on pancreatic tumor growth.(H) Quantification of tumor weights from mice in (G).(I) Absolute number of intra-tumoral B cells from mice in (H).(J) Absolute number of intra-tumoral Breg cells from mice in (H).(K) Absolute number of intra-tumoral plasma cells from mice in (H). Error bars indicate SEM; p values were calculated using two-tailed; unpaired, Student’s t test. p values in (H) to (K) were calculated using one-way ANOVA. NS, non-significant, *p < 0.05, **p < 0.005. Data are representative of three independent experiments.